The DOI matches its Crossref record; 20 of the 22 references it cites were found in a registry or an index.
Antagonism of the effects of the hallucinogen dom and the purported 5-HT agonist quipazine by 5-HT2 antagonists
Abstract
Rats trained to discriminate 1.0 mg/kg of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM) from saline in a two-lever operant choice task were administered doses of mescaline, LSD, 5-methoxy-N,N-dimethyltryptamine (5-OMe DMT), quipazine, TFMPP and RU-24969. The DOM-stimulus generalized to the three hallucinogenic agents and to quipazine, but not to the purported serotonin agonists TFMPP or RU-24969. Pretreatment of the animals with the 5-HT2 antagonists ketanserin and pirenperone antagonized the effect produced by DOM. Pirenperone also blocked DOM-stimulus generalization to mescaline, LSD, 5-OMe DMT and quipazine. The results of this study suggest that the discriminative stimulus effects of DOM, the three hallucinogenic agents to which DOM-stimulus generalization occurred, and quipazine, may involve those sub-populations of serotonin receptors that are labeled by tritiated ketanserin (i.e. 5-HT2 sites).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“To prevent any potential numerical errors, the term “classic psychedelics'' is used, referring to the category of substances that bind to serotonin receptors in the brain, with 5HT2A receptor selectivity [29].”
From Mindfulness meditation and psychedelics: potential synergies and commonalities (2023) · cites this paper as [29]
Citations
Cites
A SIMPLIFIED METHOD OF EVALUATING DOSE-EFFECT EXPERIMENTS
Litchfield, J. T., & Wilcoxon, F. (1949) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)03549-9 · Cited by 7,798
Peroutka, S. J., & Snyder, S. H. (1979) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13812-1 · Cited by 1,363
Leysen, J. E., Niemegeers, C. J. E., Nueten, J. M. V., & Laduron, P. M. (1982) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)14623-3 · Cited by 1,071
Receptor binding profile of R 41 468, A novel antagonist at 5-HT2 receptors
Leysen, J. E., Awouters, F. H. L., Kennis, L. E. J., Laduron, P. M., Vandenberk, J., & Janssen, P. A. J. (1981) · Life Sciences · doi:10.1016/0024-3205(81)90747-5 · Cited by 843
Two Distinct Central Serotonin Receptors with Different Physiological Functions
Peroutka, S. J., Lebovitz, R. M., & Snyder, S. H. (1981) · Science · doi:10.1126/science.7221567 · Cited by 639
Colpaert, F. C., Niemegeers, C. J. E., & Janssen, P. A. J. (1982) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)33038-7 · Cited by 168
Green, A. R., Youdim, M. B. H., & Smith, A. D. (1976) · Neuropharmacology · doi:10.1016/0028-3908(76)90026-5 · Cited by 120
Glennon, R. A., Rosecrans, J. A., & Young, R. (1983) · Medicinal Research Reviews · doi:10.1002/med.2610030305 · Cited by 89
Self-citationGREEN, A. R., Hall, J., & Rees, A. R. (1981) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1981.tb16806.x · Cited by 88
DOM-stimulus generalization to LSD and other hallucinogenic indolealkylamines
Glennon, R. A., Young, R., Jacyno, J. M., Slusher, M., & Rosecrans, J. A. (1983) · European Journal of Pharmacology · doi:10.1016/0014-2999(83)90196-6 · Cited by 67
Self-citationSerotonin — Current Aspects of Neurochemistry and Function
Strange, P. (1982) · Biochemical Education · doi:10.1016/0307-4412(82)90100-5 · Cited by 60
Fuller, R. W., Snoddy, H. D., Mason, N. R., & Molloy, B. B. (1978) · European Journal of Pharmacology · doi:10.1016/0014-2999(78)90016-x · Cited by 59
Silverman, P. B., & Ho, B. T. (1980) · Psychopharmacology · doi:10.1007/bf00428105 · Cited by 55
Fuller, R. W., Mason, N. R., & Molloy, B. B. (1980) · Biochemical Pharmacology · doi:10.1016/0006-2952(80)90567-5 · Cited by 54
5-Hydroxytryptamine-like properties of m-chlorophenylpiperazine: comparison with quipazine
Rokosz-Pelc, A., Antkiewicz‐Michaluk, L., & Vetulani, J. (1980) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1980.tb12896.x · Cited by 47
Chapter 1. Biochemical Models for Serotonin Receptors
McDermed, J. D., Leysen, J. E., & Tollenaere, J. P. (1982) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(08)60483-2 · Cited by 39
Hunt, P., & Oberlander, C. (1981) · Advances in experimental medicine and biology · doi:10.1007/978-1-4684-3860-4_31 · Cited by 38
Discriminative stimulus properties of the hallucinogenic agent DOM.
Young, R., Glennon, R. A., & Rosecrans, J. A. (1980) · PubMed · Cited by 31
Self-citationComparison of behavioral properties of di- and tri-methoxyphenylisopropylamines
Glennon, R. A., & Young, R. (1982) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(82)90330-6 · Cited by 28
Self-citationPharmacological studies on serotonin-mediated behaviour.
Green, A. R. (1981) · PubMed · Cited by 12
Research works printed but not linked: 3
- Leysen, 1981, Serotonergic receptors in brain tissue: properties and identification of various [3H]-ligand binding sites in vitro, J. Physiol. (Paris), 77, 351
- Leysen, 1982, [3H]-ketanserin (R 41,468), a selective 3H-ligand for serotonin2 receptor binding sites, Mol. Pharmacol., 21, 301
- Lucki, 1982, Behavioral effects of indole- and piperazine-type serotonin receptor agonists, Abstr. Soc. Neurosci., 8, 101
Cited by
Sorted by citations
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Nichols, D. E., & Nichols, C. D. (2008) · Chemical Reviews · doi:10.1021/cr078224o · Cited by 895
Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents
Glennon, R. A., Titeler, M., & MCKENNEY, J. D. J. (1984) · Life Sciences · doi:10.1016/0024-3205(84)90436-3 · Cited by 635
Self-citationNichols, D. E. (1986) · Journal of Psychoactive Drugs · doi:10.1080/02791072.1986.10472362 · Cited by 564
Metadata
- Authors
- Glennon, R. A., Young, R., & Rosecrans, J. A.
- Affiliations
- Virginia Commonwealth University (US)
- Corresponding author
- Glennon, Richard A.
- Venue
- European Journal of Pharmacology
- Publisher
- Elsevier BV
- Published
- 1983-07
- Volume
- 91
- Issue
- 2-3
- Pages
- 189-196
- ISSN
- 0014-2999 (ISSN-L)
- OpenAlex
- W1983135802
- Cited by
- 190
- References
- 22
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 5 · 2023: 7 · 2022: 6 · 2021: 2 · 2020: 7 · 2019: 1 · 2018: 5 · 2017: 1 · 2016: 4 · 2015: 2 · 2014: 3
- FWCI
- 15.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cognitive Neuroscience › Hallucinations in medical conditions
- Keywords
- DOM, 5-HT2 receptor antagonist, quipazine, ketanserin, pirenperone, mescaline, LSD, hallucinogens, TFMPP, RU 24969, serotonin receptor agonists
- MeSH terms
- Amphetamines, Animals, DOM 2,5-Dimethoxy-4-Methylamphetamine, Ketanserin, Male, Piperidines, Quinolines, Quipazine, Rats, Inbred Strains, Serotonin Antagonists, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
